Amphastar Pharmaceuticals, Inc. AMPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
4.82
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $719.9M | $98.1M | $356.1M | $121.2M | $788.8M |
| 2024 | $732.0M | $159.5M | $373.9M | $172.3M | $732.3M |
| 2023 | $644.4M | $137.5M | $351.1M | $145.3M | $639.4M |
| 2022 | $499.0M | $91.4M | $248.9M | $65.1M | $528.7M |
| 2021 | $437.8M | $62.1M | $199.7M | $70.5M | $445.5M |
| 2020 | $349.8M | $1.4M | $143.3M | $23.4M | $448.7M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.82 (safe)
- Working capital / assets 0.293
- Retained earnings / assets 0.409
- EBIT / assets 0.086
- Equity / liabilities 0.939
Source: SEC EDGAR filings · CIK 0001297184 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.